Study to Evaluate the Safety and Effectiveness of Different Doses of AP-Brain on Thinking and Attention in Healthy Young Adults with Attention Difficulties

What this Trial Is About

Researchers are evaluating the safety and effects of AP-Brain, a dietary supplement containing hydrolyzed collagen, on cognitive function in healthy younger adults who report attention problems. The study is designed as a randomized, triple-blind, placebo-controlled trial aiming to understand how different doses of AP-Brain affect cognitive abilities, with a focus on the CNS VS Neurocognitive Index NCI score and complex attention. Participants will be assigned to one of four groups AP-Brain doses of 1 gram, 3 grams, or 5 grams, or a placebo. Each dose is taken as a capsule or combination of capsules totaling five tablets during an in-clinic visit with a standardized meal. The placebo contains inactive ingredients such as microcrystalline cellulose and magnesium stearate. The treatment period lasts 56 days, during which participants consume the assigned product and complete memory and cognitive assessment questionnaires. During the study, participants will complete cognitive tests at multiple timepoints, including baseline, Day 1, Day 28, and Day 56, to measure changes in cognitive function using the CNS VS test battery. Researchers will also monitor biomarkers like brain-derived neurotrophic factor BDNF and markers of inflammation. Participants agree to maintain lifestyle habits and avoid certain substances before visits. The study includes safety monitoring and questionnaires to assess product perception, with total participation lasting about 56 days.

A Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Function at Varying Dosages in Healthy Younger Adults With Self-reported Attention Problems